Select Committee · Health and Social Care Committee

Future cancer

Status: Closed Opened: 21 Mar 2023 Closed: 30 May 2024
Inquiry scopeThe Future Cancer inquiry will explore innovations in cancer diagnosis and treatment. It will look at the innovations with the greatest potential to transform cancer diagnosis and treatment for patients in the short, medium and long term, and it will examine how innovations in diagnosing and treating cancer can best be transitioned into frontline clinical settings. It will also explore international examples of best practice. Types of innovations that could be examined by the inquiry range from medicines and vaccines to artificial intelligence. This inquiry builds on the Committee's recent work on cancer services, including its report in April 2022, which was focused largely on current provision of cancer services and the impact of the covid-19 pandemic.

Oral evidence sessions

6 sessions

On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.

Date Session and witnesses Source
29 Jan 2024
Oral Evidence
Dame Cally Palmer · NHS England, Professor Peter Johnson · NHS England, Rt Hon Andrew Stephenson · Department of Health and Social Care
View ↗
9 Jan 2024 Dr Julie Gralow · American Society of Clinical Oncology, Dr Paul Mullholland · University College London and University College London Hospitals, Professor David Baldwin · School of Medicine (University of Nottingham), Professor David Chang · University of Glasgow, Professor Mark Lawler · Queen's Univeristy Belfast View ↗
28 Nov 2023 James Hargrave · Keep Up With Cancer, Julian Beach · Medicines and Healthcare products Regulatory Agency (MHRA), Professor Paul Dalby · University College London, Sarah Byron · National Institute for Health and Care Excellence (NICE), Tony Hickson · Cancer Research Horizons and Cancer Research UK View ↗
14 Sep 2023 Dr Robin Buckle · Medical Research Council, Dr Susan Galbraith · AstraZeneca, Professor Kevin Harrington · Institute of Cancer Research, Professor Sir John Bell · Oxford University View ↗
19 Jul 2023 Marcel Gehrung, PhD · Cyted, Professor Matt Brown · Genomics England, Professor Stephen Duffy · Wolfson Institute of Population Health (Queen Mary University of London), Sara Hiom · GRAIL Europe View ↗
21 Jun 2023 Anna Jewell · Less Survivable Cancers Taskforce, Gemma Peters · Macmillan Cancer Support, Jane Lyons · Cancer52, Michelle Mitchell OBE · Cancer Research UK View ↗

Written evidence

87 submissions recorded

Submission metadata is shown here; use the source links to read the evidence on Parliament’s website.

Showing the latest 50 of 87 recorded submissions. Written evidence in the activity timeline uses this same preview. Browse the inquiry on Parliament.

On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.

ReferenceDateSubmitter
FCR0088
Full text not held
7 May 2024 Boehringer Ingelheim Ltd
FCR0087
Full text not held
7 Feb 2024 Dr Paul Mulholland, University College London
FCR0086
Full text not held
16 Jan 2024 Professor David Baldwin, Nottingham University Hospitals NHS Trust
FCR0085
Full text not held
16 Jan 2024 Maggie's
FCR0084
Full text not held
19 Dec 2023 Institute of Biomedical Science
FCR0082
Full text not held
29 Nov 2023 Open Medical
FCR0081
Full text not held
29 Nov 2023 Neil Daly, Skin Analytics
FCR0083
Full text not held
29 Nov 2023 Endoscope-i
FCR0080
Full text not held
6 Sep 2023 Cancer52
FCR0079
Full text not held
6 Sep 2023 Macmillan Cancer Support
FCR0015
Full text not held
28 Jun 2023 Professor Miriam Dwek, University of Westminster
FCR0014
Full text not held
28 Jun 2023 Brain Tumour Research
FCR0013
Full text not held
28 Jun 2023 The Newcastle upon Tyne Hospitals NHS Foundation Trust
FCR0012
Full text not held
28 Jun 2023 Boots UK
FCR0011
Full text not held
28 Jun 2023 The University of Manchester
FCR0010
Full text not held
28 Jun 2023 Dr Heather Williams, The Christie NHS Foundation Trust
FCR0009
Full text not held
28 Jun 2023 Kidney Cancer UK
FCR0008
Full text not held
28 Jun 2023 Breast Cancer Now
FCR0007
Full text not held
28 Jun 2023 Alastair Travis, Silverbird Ltd
FCR0006
Full text not held
28 Jun 2023 UK Focused Ultrasound Foundation
FCR0005
Full text not held
28 Jun 2023 Action Against Heartburn
FCR0004
Full text not held
28 Jun 2023 Yorkshire & Humber Academic Health Science Network
FCR0003
Full text not held
28 Jun 2023 Anthony Nolan
FCR0002
Full text not held
28 Jun 2023 Advanced Accelerator Applications, a Novartis company
FCR0001
Full text not held
28 Jun 2023 Prof Wladyslaw Gedroyc, Imperial College Healthcare NHS Trust
FCR0030
Full text not held
28 Jun 2023 MAP Patient Access
FCR0029
Full text not held
28 Jun 2023 Imaging and Dosimetry for Molecular Radiotherapy Glenn Flux, Royal Marsden Hospital
FCR0028
Full text not held
28 Jun 2023 Professor Stephen W. Duffy, Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London
FCR0027
Full text not held
28 Jun 2023 Leeds University Medical School
FCR0026
Full text not held
28 Jun 2023 Cyted
FCR0025
Full text not held
28 Jun 2023 Cancer Research UK Cambridge Centre
FCR0024
Full text not held
28 Jun 2023 GRAIL
FCR0023
Full text not held
28 Jun 2023 Dr Laura Wareing, Lancaster University
FCR0022
Full text not held
28 Jun 2023 NICE (National Institute for Health and Care Excellence)
FCR0021
Full text not held
28 Jun 2023 Young Lives vs Cancer
FCR0020
Full text not held
28 Jun 2023 School of Health Sciences, University of Surrey
FCR0019
Full text not held
28 Jun 2023 Mrs Claire Bode, Worcestershire Acute Hospitals NHS Trust
FCR0018
Full text not held
28 Jun 2023 Macmillan Cancer Support
FCR0017
Full text not held
28 Jun 2023 Society of Clinical Injury Lawyers
FCR0016
Full text not held
28 Jun 2023 British In Vitro Diagnostics Association (BIVDA)
FCR0045
Full text not held
28 Jun 2023 Blood Cancer UK
FCR0044
Full text not held
28 Jun 2023 The Royal College of Surgeons of Edinburgh
FCR0043
Full text not held
28 Jun 2023 18 Week Support
FCR0042
Full text not held
28 Jun 2023 AstraZeneca UK
FCR0041
Full text not held
28 Jun 2023 Society and College of Radiographers
FCR0040
Full text not held
28 Jun 2023 The Royal College of Radiologists (RCR)
FCR0039
Full text not held
28 Jun 2023 Mr Stephen West, UHCW, Walsgrave Hospital, Clifford Bridge Road, Coventry, CV2 2DX
FCR0038
Full text not held
28 Jun 2023 Cancer52
FCR0037
Full text not held
28 Jun 2023 Astellas Pharma Ltd.
FCR0036
Full text not held
28 Jun 2023 Future Targeted Healthcare Manufacturing Hub

Who gave evidence

25 witnesses

On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.

WitnessOrganisationSessions
Anna Jewell · Chair Less Survivable Cancers Taskforce 1
Dame Cally Palmer · National Cancer Director NHS England 1
Dr Julie Gralow · Executive Vice President and Chief Medical Officer American Society of Clinical Oncology 1
Dr Paul Mullholland · Honorary Associate Professor and Consultant in medical oncology University College London and University College London Hospitals 1
Dr Robin Buckle · Chief Science Officer Medical Research Council 1
Dr Susan Galbraith · Executive Vice President of Oncology Research & Development AstraZeneca 1
Gemma Peters · Chief Executive Officer Macmillan Cancer Support 1
James Hargrave · Vice-Chair Keep Up With Cancer 1
Jane Lyons · Chief Executive Officer Cancer52 1
Julian Beach · Interim Executive Director, Healthcare Quality and Access Medicines and Healthcare products Regulatory Agency (MHRA) 1
Marcel Gehrung, PhD · Co-founder and Chief Executive Officer Cyted 1
Michelle Mitchell OBE · Chief Executive Officer Cancer Research UK 1
Professor David Baldwin · Consultant Respiratory Physician and Honorary Professor of Medicine School of Medicine (University of Nottingham) 1
Professor David Chang · Co-Lead of Precision-Panc, and Chair of Surgical Oncology University of Glasgow 1
Professor Kevin Harrington · Head of the Division of Radiotherapy and Imaging Institute of Cancer Research 1
Professor Mark Lawler · Board Member (European Cancer Organisation), and Associate Pro-Vice-Chancellor and Professor of Digital Health Queen's Univeristy Belfast 1
Professor Matt Brown · Chief Scientific Officer Genomics England 1
Professor Paul Dalby · Co-Director of the Future Targeted Healthcare Manufacturing Hub; Deputy Head of the Department of Biochemical Engineering University College London 1
Professor Peter Johnson · National Clinical Director for Cancer NHS England 1
Professor Sir John Bell · Regius Professor of Medicine Oxford University 1
Professor Stephen Duffy · Professor of Cancer Screening Wolfson Institute of Population Health (Queen Mary University of London) 1
Rt Hon Andrew Stephenson · Minister of State (Minister for Health and Secondary Care) Department of Health and Social Care 1
Sara Hiom · Vice President, NHS Implementation & External Affairs GRAIL Europe 1
Sarah Byron · Programme Director of Devices, Diagnostics and Digital National Institute for Health and Care Excellence (NICE) 1
Tony Hickson · Chief Business Officer Cancer Research Horizons and Cancer Research UK 1

Correspondence

1 letter

On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.